Navigation Links
ESHRE bridges East and West for its 2012 Congress in Istanbul
Date:1/10/2011

Reproductive medicine is one of today's most exciting scientific and clinical areas. Every month there are announcements of medical 'firsts', new rulings by regulatory bodies or ethical controversies. These often spark a heated debate among practitioners in the field, ethicists, legislators, the media and the public.

ESHRE's Annual Meeting is the forum where more than 9,000 of the world's leading experts in reproductive medicine gather to give a public presentation of their latest research findings.

"The ESHRE Annual Meeting is a great opportunity to discuss progress and the latest breakthroughs in reproductive medicine. This event addresses current and emerging health science, policy and practice issues in the field. Many of the participants come to hear about cutting edge research," says Dr. Luca Gianaroli, current ESHRE chairman. "Nothing illustrates the achievements of reproductive medicine more than the fact that in some European countries up to 5% of children are born using assisted reproduction technologies. With an ever-so-fast changing field, our Annual Congress is the world's premier reproductive science conference."

During the four day meeting, issues that present policy-makers and ethicists with some of the most challenging problems and difficult decisions will be discussed. "We are particularly delighted that ESHRE, for the first time, holds its meeting in Istanbul. Located on two continents ESHRE's Annual Meeting in Istanbul will bridge the border between East and West, hopefully attracting more participants from the Middle and Far East, India and Russia," says Dr. Anna Veiga, chairman elect, who will preside over the meeting as future chairman.

Istanbul in the summer is a charming and exhilarating venue. It is endowed with unrivalled beauty and complimented by a unique juxtaposition of
'/>"/>

Contact: Hanna Hanssen
hanna@eshre.eu
322-263-6466
European Society of Human Reproduction and Embryology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Glidewell Dental Lab Introduces BruxZir Solid Zirconia Crowns and Bridges
2. mHealth Alliance Works in Partnership with GSMA to Expand Discussion of Mobile Health at 2010 Mobile World Congress
3. NGA Focus on States Health Care Responsibilities Spotlights Need for Congress to Pass Federal Medicaid Relief
4. Physician Assistants Call on Congress for Policies That Promote High-Quality Patient Care
5. Congressional Staff Briefing, Wed., Feb. 24 on Mental Health, Medicaid & Block Grants
6. Bread for the World, USDA Secretary Urge Congress to End Child Hunger in U.S.
7. The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies Failure to Provide Adequate Safety Research
8. NSBA Implores Congress to Act on Health Care Reform
9. DNC Chairman Tim Kaine Applauds President, Members of Congress on Todays Bipartisan Summit
10. FASEB President Addresses Congressional Audience at Coalition for Health Funding Briefing on Public Health
11. Congresswoman Maloney To Be Keynote Speaker: Momentum Builds for Hysterectomy Informed Consent Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 The FSH Society , ... the little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), ... . The purpose of the campaign is to spread ... most common forms of muscular dystrophies. , To ... the FSH Society will begin sharing impactful photographs of ...
(Date:3/3/2015)... Presale tickets for Madonna will be ready for purchase ... March 9, with Madonna tour tickets expected to sell out ... talented artist is a significant one for fans, and the ... Ticketability.com to browse the inventory of Madonna tickets at ... enjoy, the 2015 tour is expected to attract attention from ...
(Date:3/3/2015)... 2015 State after state prove ... of probation programs aimed to rehabilitate nonviolent drug ... (tax) cost of incarcerating violators of drug laws, ... alcohol addiction treatment. Governor Bruce Rauner ( R)has ... Illinois' drug and alcohol statewide Department of Alcoholism ...
(Date:3/3/2015)... Using an “intelligent,” rather than random, method ... prescription drug coverage plans could save Medicare and patients ... Pittsburgh Graduate School of Public Health analysis discovered. ... of the journal Health Affairs and build upon an ... than $5 billion in its Part D low-income subsidy ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Volpara Solutions, ... announced that John D. Pavlidis has joined their Board ... of technical and executive management experience in the medical ... large and small organizations. , “John’s broad management experience ... imaging modalities will be a tremendous asset to the ...
Breaking Medicine News(10 mins):Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 2Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 3Health News:Presale Tickets for Madonna: Ticketability.com Announces Madonna Tour Tickets for Sale at Reduced Prices for the Rebel Heart Tour During Presales 2Health News:Gov. of Illinois, Bruce Rauner, Suggests Cutting 25 Million for Drug Rehabilitation, Harbor Village Comments 2Health News:Medicare and Patients with Schizophrenia Could Save $150 Million on Part D Plans 2Health News:Medicare and Patients with Schizophrenia Could Save $150 Million on Part D Plans 3Health News:Volpara Solutions Adds Medical Imaging Veteran John Pavlidis to Board of Directors 2Health News:Volpara Solutions Adds Medical Imaging Veteran John Pavlidis to Board of Directors 3
... numbers are staggering --,over 20% of people living in ... the impairment or disability which creates dependency and,poverty in ... and political opportunities," says Ron Nabors, Chief,Executive Officer of ... stand up and speak out on the,International Day for ...
... Oct. 16 Children in the South Bay,suffering ... conditions can,now receive specialty care from Lucile Packard ... hospital,s new South Bay,Specialty Center in Los Gatos ... all the hallmarks of its parent institution. ...
... WEST CHESTER, Ohio, Oct. 16 AtriCure, Inc.,(Nasdaq: ... leader in cardiac surgical,ablation products, today announced that ... which physicians have adopted to,treat atrial fibrillation (AF), ... Dr. James H. McClelland, an,electrophysiologist, and colleagues from ...
... the U.S. Food and Drug,Administration,s (FDA,s) Cardiovascular ... majority of members voted to recommend the ... FOSRENOL(R),(lanthanum carbonate), to treat hyperphosphatemia (elevated levels ... disease (CKD) Stage 4 patients.,Currently, FOSRENOL is ...
... and Advertising ... Distribution Agreements, WebMD Announces Third Quarter Earnings ... WebMD Health Corp. (Nasdaq:,WBMD), the leading provider of health information services, ... Preliminary Results for the Three Months Ended September 30, 2007 ...
... Oct. 16 HLTH Corporation,(Nasdaq: HLTH ) today ... months ended September 30, 2007 at approximately 4:00 pm ... previously announced, HLTH Corporation,s 84% owned,subsidiary, WebMD Health Corp. ... their financial results for the three months ended September ...
Cached Medicine News:Health News:CBM USA stands up and speaks out to world leaders on the International Day for the Eradication of Poverty 2Health News:Packard Children's Hospital Opens New South Bay Specialty Clinic Bringing Specialty Care Close to Home 2Health News:Published Results Using AtriCure Minimally Invasive Products 2Health News:Published Results Using AtriCure Minimally Invasive Products 3Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 2Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 3Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 4Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 5Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 6Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 7Health News:WebMD Reports Preliminary Third Quarter Financial Results 2Health News:WebMD Reports Preliminary Third Quarter Financial Results 3Health News:WebMD Reports Preliminary Third Quarter Financial Results 4Health News:WebMD Reports Preliminary Third Quarter Financial Results 5Health News:WebMD Reports Preliminary Third Quarter Financial Results 6Health News:WebMD Reports Preliminary Third Quarter Financial Results 7Health News:WebMD Reports Preliminary Third Quarter Financial Results 8Health News:WebMD Reports Preliminary Third Quarter Financial Results 9Health News:WebMD Reports Preliminary Third Quarter Financial Results 10Health News:WebMD Reports Preliminary Third Quarter Financial Results 11Health News:HLTH Corporation Announces Third Quarter Earnings Release Date and Conference Call 2
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research and ... addition of Jain PharmaBiotech,s new report "Cardiovascular Drug ... offering. , Drug delivery to the ... because of the anatomy and physiology of the vascular ... of the body. Drugs can be introduced into the ...
(Date:3/3/2015)... 2015  Delcath Systems, Inc. (NASDAQ: ... company focused on oncology with an emphasis on ... announces that the results from its Phase 3 ... been submitted for publication in a leading peer-reviewed ... for Injection for use with the Delcath Hepatic ...
(Date:3/3/2015)... Depomed, Inc. (NASDAQ: DEPO ) today ... Annual Roth Conference in Laguna Niguel ... (9:30 am PT) Tuesday, March 10, 2015. The ... via the Investor Relations page of the Depomed website at ... archived for 30 days on the company,s website. ...
Breaking Medicine Technology:Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 2Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 3Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 2Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 3Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 4Depomed To Present At 27th Annual Roth Conference 2
... control ... with combination therapy -, ... study presents,data demonstrating that patients with Chronic Obstructive Pulmonary ... and symptom control when treated with a,combination of nebulized ...
... Presented at the 2008 International Conference of the American ... ... May 20 Forest Laboratories, Inc. and,Laboratorios Almirall, S.A. today ... of aclidinium bromide, an,investigational treatment for chronic obstructive pulmonary disease ...
Cached Medicine Technology:Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 2Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 3Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 4Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 5Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 6Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 7Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 2Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 3Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 4Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 5
The STAAR ELASTIMIDE™ lens, combines the best of foldable lens technology with traditional design. This lens contains a cast-molded, silicone optic with modified Polyimide haptics....
The STAAR ELASTIC LENS®, is a single piece silicone lens to be placed completely in the capsular bag....
Foldable Silicone Multi-piece Lens....
... Lomb UV-Absorbing, Silicone Posterior Chamber Intraocular Lens ... for the visual correction of aphakia in ... in whom the cataractous lens has been ... device is intended to be placed only ...
Medicine Products: